Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Johnson and Johnson
Moodys
McKesson

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Patent: 7,601,520

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,601,520
Title:Method for rapid identification of porcine insulin-like growth factor 2 intron 7 point mutation
Abstract: A method for rapidly identifying a point mutation in porcine insulin-like-growth factor 2 intron 7 uses published primers to amplify the target DNA fragments by polymerase chain reaction. The DNA fragments are cloned and sequenced for confirmation and method validation. The key positions of the sequence are modified to generate three primers for amplifying different DNA fragments with different genotypes by PCR to avoid additional restriction enzyme digestion. A long primer is used to specifically amplify the lean muscle mass-enhancing allele, a short primer is used to specifically amplify the lean muscle mass-suppressing allele, and the third primer is shared and anneals to the complementary strand. After PCR and electrophoresis, samples with only the 92 bp band are identified as the CC genotype, samples with only the 72 bp band are identified as the GG genotype, and samples with both 92 bp and 72 bp bands are identified as heterozygotes.
Inventor(s): Chang; Hsiu-Luan (Neipu Township, Pingtung County, TW), Wu; Ming-Che (Neipu Township, Pingtung County, TW), Chu; Chia Te (Neipu Township, Pingtung County, TW)
Assignee:
Application Number:11/598,659
Patent Claims:see list of patent claims

Details for Patent 7,601,520

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
McKesson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.